WO2023189643A1 - カルコン含有製剤 - Google Patents

カルコン含有製剤 Download PDF

Info

Publication number
WO2023189643A1
WO2023189643A1 PCT/JP2023/010245 JP2023010245W WO2023189643A1 WO 2023189643 A1 WO2023189643 A1 WO 2023189643A1 JP 2023010245 W JP2023010245 W JP 2023010245W WO 2023189643 A1 WO2023189643 A1 WO 2023189643A1
Authority
WO
WIPO (PCT)
Prior art keywords
mass
component
formulation
parts
chalcone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/010245
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
夕子 渡辺
あやの 井上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haruna Produce Inc
Original Assignee
Haruna Produce Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruna Produce Inc filed Critical Haruna Produce Inc
Priority to JP2024511780A priority Critical patent/JPWO2023189643A1/ja
Publication of WO2023189643A1 publication Critical patent/WO2023189643A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to formulations containing chalcone.
  • Angelica keiskei (scientific name: Angelica keiskei) is a plant belonging to the Apiaceae family and the genus Shishiudo.
  • Ashitaba is a plant native to Japan, and is known to grow wild in the southern part of the Kanto region and westward, from the Boso Peninsula to the southern Kii Peninsula and the Pacific coast of the Izu Islands.
  • Non-Patent Document 1 When the stems and leaves of Ashitaba are cut, a highly viscous dark yellow juice comes out. This liquid called yellow juice contains chalcones, etc., which have beauty and health effects in addition to antibacterial effects, and Ashitaba is also used as a material for medicinal purposes and health foods (Non-Patent Document 1).
  • the yellow juice obtained from Ashitaba contains chalcone, but chalcone is poorly water-soluble, and when the concentration increases, the dispersion stability when made into a formulation deteriorates. Therefore, conventional chalcone-containing formulations contain chalcone at low concentrations.
  • chalcone is a component with various physiological activities, so there has been a demand for a formulation with a high chalcone concentration and high dispersion stability.
  • an object of the present invention is to provide a formulation with a high chalcone concentration and high dispersion stability.
  • the present invention includes the following aspects.
  • a preparation with improved dispersion stability can be provided by allowing a specific solubilizing component to coexist with a high concentration of chalcone.
  • FIG. 1 is a photograph showing the solubility of a test formulation in a comparative example.
  • FIG. 2 is a photograph showing the solubility of the test formulation in each Example.
  • FIG. 3 is a photograph showing the solubility of the test formulation in each Example.
  • FIG. 4 is a photograph showing the solubility of the test formulations in each example.
  • FIG. 5 is a photograph showing the solubility of the test formulation in each Example.
  • FIG. 6 is a photograph showing the solubility of the test formulation in each Example.
  • FIG. 7 is a photograph showing the solubility of the test formulation in each Example.
  • FIG. 8 is a photograph showing the solubility of the test formulation in each Example.
  • FIG. 9 is a photograph showing the solubility of the test formulation in each Example.
  • FIG. 10 is a photograph showing the solubility of the test formulation in each example.
  • the formulation includes (A) chalcone, and (B) at least one selected from the group consisting of sucrose fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, enzymatically decomposed lecithin, and saponin. Contains solubilizing ingredients.
  • Chalcone is known to have a 2',4-dihydroxychalcone skeleton represented by the following formula (1) as a basic skeleton.
  • chalcone preferably has a geranyl group at the 3' position of the basic skeleton and/or a lower alkoxy group at the 4' position.
  • chalcones for example, chalcones derived from A. reticulata are preferred, and at least one chalcone selected from the group consisting of 4-hydroxydericin and xanthoangelol is more preferred.
  • 4-hydroxydericin has a methoxy group at the 4' position of the basic skeleton, and is represented by the following formula (2).
  • Xanthoangelol has a geranyl group at the 3' position of the basic skeleton, and is represented by the following formula (3).
  • the content of xanthoangelol per 1 part by mass of 4-hydroxydericin is not limited as long as the effects of the present invention are achieved, but for example, 0.1 to 10 parts by mass, 0. Examples include 5 to 5 parts by weight, 1.0 to 3 parts by weight, and 1.5 to 2.5 parts by weight.
  • chalcone there are no particular limitations on the production method or method of obtaining chalcone, but for example, it may be derived from A. reticulata, may be synthesized using a known method, or a commercially available product may be used.
  • yellow juice derived from Ashitaba As the chalcone derived from Ashitaba, it is also possible to use yellow juice derived from Ashitaba.
  • Yellow juice derived from Angelica napus can be obtained from the whole or a part of the Angelica napus plant, such as at least one selected from the group consisting of leaves, stems, roots, seeds, and flowers.
  • the solid content of yellow juice derived from Angelica napus for example, a processed product obtained by subjecting the whole plant, roots, stems, leaves, etc. of Angelica Angelica to pulverization, crushing, grinding, pressing, etc. can be used.
  • an extract obtained by extracting the above-mentioned processed product or yellow juice with a solvent is also possible to use an extract obtained by extracting the above-mentioned processed product or yellow juice with a solvent as chalcones derived from Ashitaba.
  • the extraction method is not particularly limited.
  • the extract of Ashitaba is obtained from the whole or a part of the Ashitaba plant, such as at least one fresh or dried plant selected from the group consisting of leaves, stems, roots, seeds, and flowers. Alternatively, they can be appropriately cut, crushed or crushed into powder, and then extracted with a solvent.
  • Examples of the solvent used for extraction include water, organic solvents, and water-containing organic solvents.
  • an aqueous extract, an organic solvent extract, or a water-containing organic solvent extract of Angelica oleracea can be obtained.
  • These extraction solvents include, but are not limited to, water, methanol, ethanol, ethylene glycol, 1,3-butylene glycol, isopropylene glycol, propylene glycol, glycerin, ethyl acetate, isopropyl alcohol, tetrahydrofuran, n-propanol, methyl ethyl ketone, Dioxane, acetone, acetonitrile, acetic acid, dimethylformamide, n-hexane or mixtures thereof are preferred.
  • the concentration of the solvent is not limited, but from the viewpoint of obtaining higher extraction efficiency, it is used at a concentration of, for example, 100% to 40%, preferably 100% to 60%, more preferably 100% to 80%. I can do it.
  • the extraction temperature is not limited, but from the viewpoint of obtaining higher extraction efficiency, it can be, for example, 20 to 100°C, preferably 22 to 80°C, and more preferably 25 to 60°C.
  • the extraction time is not limited, but from the viewpoint of obtaining higher extraction efficiency, it can be, for example, from 5 minutes to 14 days, preferably from 10 minutes to 7 days, and from 15 minutes to 5 days. More preferred.
  • the operation of adding and stirring the extraction solvent can be performed using a known method.
  • examples include a method of mixing by installing in a mechanical stirring device, a method of shaking the extraction container, and the like.
  • the same type or multiple types of extraction solvents are further added to the residue obtained in the first stage extraction, and after heating at room temperature or heating, the extract of Asitaba is separated and extracted from the extraction supernatant. be able to.
  • the extraction supernatant can be used as it is as an extract of Asitaba. Furthermore, it is also possible to separate and extract the solid content of yellow juice derived from Angelica japonica from the extraction supernatant. In this separation and extraction step, known methods can be employed, such as filtration, centrifugation, suction, and compression.
  • chromatographic method for example, column chromatography using a normal phase or reversed phase carrier or ion exchange resin, high performance liquid chromatography, thin layer chromatography, or centrifugal liquid chromatography, or A method using a combination of these methods may be mentioned.
  • purification conditions such as a carrier and an elution solvent can be appropriately selected depending on various chromatographic methods.
  • the content of component (A) is 0.5% by mass or more, 0.6% by mass or more, 0.7% by mass or more, 0.0% by mass or more, based on the total amount of the preparation. .8% by mass or more, 0.9% by mass or more, 1.0% by mass or more, 1.1% by mass or more, 1.2% by mass or more, 1.3% by mass or more, 1.4% by mass or more, 1.
  • the content of component (A) can be 40% by mass or less, 35% by mass or less, 32% by mass or less, 30% by mass or less, based on the total amount of the preparation. % or less, 28 mass% or less, 25 mass% or less, 22 mass% or less, 20 mass% or less, 15 mass% or less, 12 mass% or less, 10 mass% or less, 5 mass% or less, etc. .
  • the content of component (A) can be, for example, 0.5 to 40% by mass, 0.6 to 40% by mass, 0.6 to 40% by mass, based on the total amount of the preparation. .7 to 40% by mass, 0.8 to 40% by mass, 0.9 to 40% by mass, 1.0 to 40% by mass, 1.1 to 40% by mass, 1.2 to 40% by mass, 1.3 ⁇ 40% by mass, 1.4-40% by mass, 1.5-40% by mass, 0.5-35% by mass, 0.6-35% by mass, 0.7-35% by mass, 0.8-35 Mass%, 0.9 to 35 mass%, 1.0 to 35 mass%, 1.1 to 35 mass%, 1.2 to 35 mass%, 1.3 to 35 mass%, 1.4 to 35 mass% , 1.5-35% by mass, 0.5-32% by mass, 0.6-32% by mass, 0.7-32% by mass, 0.8-32% by mass, 0.9-32% by mass, 1 .0 to 32 mass%, 1.1 to 32 mass%, 1.2 to 32 mass,
  • the content of component (A) can be, for example, 0.5-30% by mass, 0.6-25% by mass, 0.7-25% by mass, based on the total amount of the preparation. It is also possible to set it to 20% by mass, 0.8 to 15% by mass, 0.9 to 10% by mass, 1.0 to 5% by mass, etc.
  • component B solubilizing component
  • component B was selected from the group consisting of sucrose fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, enzymatically decomposed lecithin, and saponin. It has been found that dispersion stability is improved by coexisting at least one solubilizing component.
  • Component (B) is preferably at least one selected from the group consisting of, but not limited to, sucrose fatty acid ester, glycerin fatty acid ester, enzymatically decomposed lecithin, and saponin, and sucrose fatty acid ester, glycerin fatty acid ester, and At least one selected from the group consisting of saponins is more preferred.
  • These B components may be synthesized and used, or commercially available products may be used.
  • sucrose fatty acid ester is not limited as long as it achieves the effects of the present invention, but examples include sucrose laurate, sucrose myristate, sucrose palmitate, sucrose stearate, and sucrose oleate. Examples include ester, sucrose behenic acid ester, sucrose erucic acid ester, etc., and one type may be used alone or two or more types may be used in combination. Examples of commercially available sucrose fatty acid esters include Ryoto Sugar Ester (manufactured by Mitsubishi Chemical Corporation).
  • Glycerin fatty acid esters are not limited as long as they achieve the effects of the present invention, but include, for example, monoglycerin fatty acid esters (glyceryl monostearate, etc.), polyglycerin fatty acid esters (decaglycerin stearate, pentaglycerin stearate, etc.). (diglycerin palmitate ester, etc.), polyglycerin condensed ricinoleate ester, organic acid monoglyceride, etc., and one type may be used alone or two or more types may be used in combination.
  • glycerin fatty acid esters examples include Poem DO-100V (manufactured by Riken Vitamin Co., Ltd.), Ryoto Polyglyester (manufactured by Mitsubishi Chemical Co., Ltd.), and Sunsoft Q (manufactured by Taiyo Kagaku Co., Ltd.).
  • the polyoxyethylene sorbitan fatty acid ester is not limited as long as it achieves the effects of the present invention, but examples include polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monomyristate, polyoxyethylene sorbitan monopalmitate, and polyoxyethylene sorbitan monomyristate.
  • Polyoxyethylene sorbitan stearate, polyoxyethylene sorbitan monooleate, etc. may be mentioned, and one type may be used alone or two or more types may be used in combination.
  • Commercially available polyoxyethylene sorbitan fatty acid esters include, for example, Emazol (manufactured by Kao Corporation).
  • the enzymatically decomposed lecithin is not limited as long as it exhibits the effects of the present invention, but any lecithin that has been subjected to the action of phospholipase A2 to hydrolyze the ester bond of the fatty acid at the 2-position may be used.
  • the lecithin used as a raw material is not limited, but examples thereof include soybean lecithin, egg yolk lecithin, etc., and one type may be used alone or two or more types may be used in combination.
  • Commercially available enzymatically decomposed lecithins include, for example, Sunlecithin (manufactured by Taiyo Kagaku Co., Ltd.).
  • Saponin is a general term for glycosides having sapogenin as an aglycone, and examples thereof include Quillaja saponin extracted from the bark of Quillaja of the Rosaceae family, although it is not limited as long as the effect of the present invention is achieved. Alternatively, two or more types may be used in combination. Examples of commercially available saponins include Quillayanin (manufactured by Maruzen Pharmaceutical Co., Ltd.).
  • the total content of component (B) can be, for example, 0.01 to 95% by mass, and 0.05 to 94% by mass, based on the total amount of the preparation, from the viewpoint of obtaining higher effects of the present invention. It is preferably 0.1 to 93% by mass, more preferably 0.5 to 92% by mass. In another embodiment, the total content of component (B) is, based on the total amount of the preparation, for example, 0.01 to 40% by mass, 0.05 to 40% by mass, 0.1 to 40% by mass, 0.5-40% by mass, 0.01-30% by mass, 0.05-30% by mass, 0.1-30% by mass, 0.5-30% by mass, 0.01-25% by mass, 0.
  • the content of the sucrose fatty acid ester alone can be, for example, 0.01 to 95% by mass, and 0.05 to 95% by mass, based on the total amount of the preparation. 94% by mass is preferred, 0.1 to 93% by mass is more preferred, even more preferably 0.5 to 92% by mass, even more preferably 0.5 to 50% by mass, and even more preferably 0.5 to 45% by mass. Preferably, 0.5 to 40% by weight is even more preferable, and even more preferably 0.5 to 35% by weight.
  • the content of the sucrose fatty acid ester alone is, for example, 0.01 to 30% by mass, 0.05 to 30% by mass, 0.1 to 30% by mass, based on the total amount of the preparation. 0.5-30% by mass, 1.0-30% by mass, 0.01-28% by mass, 0.05-28% by mass, 0.1-28% by mass, 0.5-28% by mass, 1. 0-28% by mass, 0.01-26% by mass, 0.05-26% by mass, 0.1-26% by mass, 0.5-26% by mass, 1.0-26% by mass, etc. It is possible.
  • the content of the glycerin fatty acid ester alone can be, for example, 0.01 to 95% by mass, based on the total amount of the preparation, and 0.05 to 94% by mass. %, more preferably 0.1 to 93% by mass, even more preferably 0.5 to 92% by mass, even more preferably 0.5 to 50% by mass, even more preferably 0.5 to 45% by mass, Even more preferably 0.5 to 40% by weight, even more preferably 0.5 to 35% by weight.
  • the content of glycerin fatty acid ester alone is, for example, 0.01 to 30% by mass, 0.05 to 30% by mass, 0.1 to 30% by mass, 0.
  • the content of the polyoxyethylene sorbitan fatty acid ester alone can be, for example, 0.01 to 99% by mass based on the total amount of the preparation, It is preferably 0.05 to 94% by weight, more preferably 0.1 to 93% by weight, even more preferably 1.0 to 92% by weight, and particularly preferably 3 to 91% by weight.
  • the content of polyoxyethylene sorbitan fatty acid ester alone is, for example, 50 to 99% by mass, 60 to 99% by mass, 70 to 99% by mass, 80 to 99% by mass, based on the total amount of the preparation. %, 50-95% by mass, 60-95% by mass, 70-95% by mass, 80-95% by mass, 50-92% by mass, 60-92% by mass, 70-92% by mass, 80-92% by mass, etc. It is also possible to do this.
  • the content of enzymatically decomposed lecithin alone can be, for example, 0.01 to 16% by mass, based on the total amount of the preparation, and 0.05 to 14% by mass. %, more preferably 0.1 to 12% by weight, even more preferably 0.5 to 10% by weight.
  • the content of saponin alone can be, for example, 0.01 to 16% by mass, preferably 0.05 to 14% by mass, based on the total amount of the preparation.
  • the amount is more preferably 0.1 to 12% by weight, and even more preferably 0.5 to 10% by weight.
  • the content of saponin alone is, for example, 0.01 to 25% by mass, 0.05 to 25% by mass, 0.1 to 25% by mass, 0.5% by mass, based on the total amount of the preparation.
  • the content ratio of the component (A) and the component (B) is not particularly limited, but from the viewpoint of significantly achieving the effects of the present invention, the total content of the component (B) is based on 1 part by mass of the component (A).
  • the amount can be, for example, 0.1 to 100 parts by weight, preferably 0.5 to 80 parts by weight, more preferably 0.8 to 60 parts by weight, even more preferably 1.0 to 50 parts by weight, Particularly preferred is 1 to 45 parts by weight.
  • the total content of component (B) is, for example, 0.1 to 40 parts by mass, 0.5 to 40 parts by mass, 1.
  • the total content of sucrose fatty acid ester may be, for example, 0.1 to 100 parts by mass per 1 part by mass of component (A). It is preferably 0.5 to 90 parts by weight, more preferably 0.8 to 80 parts by weight, even more preferably 1.0 to 70 parts by weight, and particularly preferably 1.0 to 60 parts by weight.
  • the total content of glycerin fatty acid ester can be, for example, 0.1 to 100 parts by mass with respect to 1 part by mass of component (A), It is preferably 0.5 to 90 parts by weight, more preferably 0.8 to 80 parts by weight, even more preferably 0.8 to 70 parts by weight, and particularly preferably 0.8 to 60 parts by weight.
  • the total content of polyoxyethylene sorbitan fatty acid ester is, for example, 0.1 to 50 parts by mass with respect to 1 part by mass of component (A). It is preferably 0.5 to 48 parts by weight, more preferably 0.8 to 46 parts by weight, and even more preferably 1.0 to 44 parts by weight.
  • the total content of enzymatically decomposed lecithin can be, for example, 0.1 to 16 parts by mass with respect to 1 part by mass of component (A), It is preferably 0.5 to 14 parts by weight, more preferably 0.8 to 12 parts by weight, and even more preferably 1.0 to 10 parts by weight.
  • the total content of saponin can be, for example, 0.1 to 100 parts by mass, and 0.5 to 100 parts by mass, per 1 part by mass of component (A). It is preferably 90 parts by weight, more preferably 0.8 to 80 parts by weight, even more preferably 0.8 to 70 parts by weight, and particularly preferably 0.8 to 60 parts by weight.
  • component (C component) in addition to the above-mentioned components, from the viewpoint of significantly achieving the effects of the present invention, as component (C), from the group consisting of propylene glycol, starch syrup, reduced starch syrup, glycerin, sugar alcohol, monosaccharides, dextrin, and maltodextrin. It is preferable to contain at least one selected from the group consisting of propylene glycol, starch syrup, reduced starch syrup, glycerin, sugar alcohols, and monosaccharides. , starch syrup, glycerin, maltitol, erythritol, sorbitol, xylitol, glucose, fructose, galactose, and mannose.
  • B components may be synthesized and used, or commercially available products may be used.
  • Examples of commercially available starch syrup include Tetra Sweet (manufactured by Nippon Cornstarch Co., Ltd.).
  • Examples of commercially available reduced starch syrup include SE 600 (manufactured by Bussan Food Co., Ltd.).
  • Examples of commercially available dextrins include Fibersol 2 (indigestible dextrin), Max 1000 (all manufactured by Matsutani Chemical Co., Ltd.), and CAVAMAX (cyclodextrin, manufactured by CycloChem Co., Ltd.).
  • Commercially available maltodextrins include, for example, Max 2000N and TK-16 (manufactured by Matsutani Chemical Co., Ltd.).
  • the total content of component (C) can be, for example, 0.01 to 95% by mass, and 0.05 to 94% by mass, based on the total amount of the preparation, from the viewpoint of obtaining higher effects of the present invention. It is preferably 0.1 to 93% by mass, more preferably 0.5 to 92% by mass. In another embodiment, the total content of component (C) is, for example, 1.0 to 95% by mass, 5 to 95% by mass, 10 to 95% by mass, 15 to 95% by mass, based on the total amount of the preparation. %, 20-95% by mass, 25-95% by mass, 30-95% by mass, 35-95% by mass, 40-95% by mass, 45-95% by mass, 50-95% by mass, etc. be.
  • propylene glycol when contained as component (C), the content of propylene glycol alone can be, for example, 0.01 to 96% by mass, and 0.05 to 94% by mass, based on the total amount of the preparation. It is preferably 0.1 to 92% by mass, more preferably 0.5 to 90% by mass.
  • the content of starch syrup alone can be, for example, 0.01 to 96% by mass, preferably 0.05 to 94% by mass, based on the total amount of the preparation. More preferably 0.1 to 92% by weight, even more preferably 0.5 to 90% by weight.
  • the content of the reduced starch syrup alone can be, for example, 0.01 to 96% by mass, and 0.05 to 94% by mass, based on the total amount of the preparation. It is preferably 0.1 to 92% by mass, more preferably 0.5 to 90% by mass.
  • the content of glycerin alone can be, for example, 0.01 to 96% by mass, preferably 0.05 to 94% by mass, based on the total amount of the preparation. More preferably 0.1 to 92% by weight, even more preferably 0.5 to 90% by weight.
  • the content of the sugar alcohol alone can be, for example, 0.01 to 96% by mass, and 0.05 to 94% by mass, based on the total amount of the preparation. It is preferably 0.1 to 92% by mass, more preferably 0.5 to 90% by mass.
  • the content of the monosaccharide alone can be, for example, 0.01 to 96% by mass, and 0.05 to 94% by mass, based on the total amount of the preparation. It is preferably 0.1 to 92% by mass, more preferably 0.5 to 90% by mass.
  • the content of dextrin alone can be, for example, 0.01 to 96% by mass, preferably 0.05 to 94% by mass, based on the total amount of the preparation. More preferably 0.1 to 92% by weight, even more preferably 0.5 to 90% by weight.
  • the content of maltodextrin alone can be, for example, 0.01 to 96% by mass, and 0.05 to 94% by mass, based on the total amount of the preparation. It is preferably 0.1 to 92% by mass, more preferably 0.5 to 90% by mass.
  • the content ratio of the (A) component and the (C) component is not particularly limited, but from the viewpoint of significantly achieving the effects of the present invention, the total content of the (C) component with respect to 1 part by mass of the (A) component.
  • the amount can be, for example, 0.01 to 100 parts by weight, preferably 0.05 to 100 parts by weight, more preferably 0.1 to 98 parts by weight, even more preferably 0.5 to 96 parts by weight, Particularly preferred is 1.0 to 95 parts by weight.
  • the total content of component (C) is, for example, 0.1 to 95 parts by mass, 0.5 to 95 parts by mass, 1.
  • the formulation may be an aqueous formulation (mainly containing an aqueous or hydrophilic base or carrier) or an oil-based formulation (mainly containing an oily or hydrophobic base or carrier). ).
  • the water content in the case of an aqueous preparation is, for example, preferably 50% by mass or more, more preferably 75% by mass or more, and even more preferably 90% by mass or more, based on the total amount of the preparation. Further, it may be 95% by mass or more, or 98% by mass or more. Further, the base or carrier may consist only of water.
  • the water content in the case of an oil-based preparation is, for example, preferably less than 50% by mass, more preferably 30% by mass or less, even more preferably 20% by mass or less, particularly preferably 10% by mass or less, based on the total amount of the preparation.
  • the formulation may be contained in a human or animal pharmaceutical composition, quasi-drug, food/beverage composition, or feed.
  • the formulation may first be formulated to be used by being incorporated into the pharmaceutical composition, quasi-drug, food/beverage composition, or feed, and then incorporated into these.
  • the formulation of the present invention may be a cosmetic food or drink composition.
  • Food and drink compositions include functional foods (including foods with functional claims), foods for patients, and foods for specified health uses, as necessary.
  • the forms of the food and drink compositions mentioned above include milk drinks, lactic acid bacteria drinks, carbonated drinks, fruit drinks (e.g. fruit juice drinks, fruit juice-containing soft drinks, fruit juice-containing carbonated drinks, fruit pulp drinks), vegetable drinks, vegetable and fruit drinks, and liqueurs.
  • fruit drinks e.g. fruit juice drinks, fruit juice-containing soft drinks, fruit juice-containing carbonated drinks, fruit pulp drinks
  • vegetable drinks vegetable and fruit drinks, and liqueurs.
  • Beverages such as alcoholic drinks, coffee drinks, powdered drinks, sports drinks, supplement drinks, etc.; Tea beverages such as black tea, green tea, and blended tea (beverages and tea beverages are included in "beverages”); Puddings such as custard pudding, milk pudding, and fruit juice pudding; desserts such as jelly, Bavarois, and yogurt; Frozen desserts such as ice cream, ice milk, lacto ice, and frozen desserts; Gums such as chewing gum and bubble gum (e.g. sheet gum, sugar-coated granular gum); Chocolates such as coated chocolate (e.g. marble chocolate, etc.), flavored chocolate (e.g. strawberry chocolate, blueberry chocolate, melon chocolate, etc.); Candies such as hard candies (e.g.
  • the food and drink compositions can also contain things that are used as food additives, similar to normal food and drink products.
  • suitable additives include acesulfame K, sucralose, aspartame, advantame, saccharin, neotame, thaumatin, monellin, monatin, Luo Han fruit extract, licorice extract, glycyrrhizin, stevia extract, stevia enzyme treatment. and high-intensity sweeteners such as rebaudioside A and stevioside.
  • acids such as chelating agents; fragrances. ; a spice extract; a preservative; a preservative; a pH adjuster; a stabilizer; a surfactant other than the above, and the like may be contained.
  • the content of the preparation contained in the food and drink composition is preferably 0.01 to 100% by mass, more preferably 0.1 to 50% by mass, and preferably 0.2 to 25% by mass. Even more preferred.
  • a formulation of the invention may be a pharmaceutical composition.
  • the dosage forms of pharmaceutical compositions include tablets (including troches and chewables), pills, capsules, granules, powders, syrups, intravenous injections, intramuscular injections, Examples include suppositories, inhalants, transdermal absorption agents, eye drops, and nasal drops.
  • Examples of "quasi-drugs” include nutritional aids, various supplements, toothpastes, mouth fresheners, odor preventive agents, hair tonics, hair growth agents, skin moisturizers, and the like.
  • oral preparations in various dosage forms, other pharmaceutically acceptable excipients, binders, fillers, disintegrants, surfactants, lubricants, dispersants, Buffers, preservatives, flavoring agents, fragrances, coating agents, carriers, diluents, other medicinal ingredients, etc. can be appropriately combined.
  • oral administration in order to prepare such pharmaceutical preparations in various dosage forms, other pharmaceutically acceptable excipients, binders, fillers, disintegrants, surfactants, lubricants, dispersants, Buffers, preservatives, flavoring agents, fragrances, coating agents, carriers, diluents, other medicinal ingredients, etc.
  • oral liquid preparations can be prepared by conventional methods by adding flavoring agents, buffers, stabilizers, and the like.
  • the content of the preparation contained in the pharmaceutical composition is preferably 0.01 to 100% by mass, more preferably 0.1 to 50% by mass, and even more preferably 0.2 to 25% by mass. More preferred.
  • the formulation of the invention may be a feed.
  • Feeds include small animal feeds used for rabbits, rats, mice, etc., pet foods used for dogs, cats, etc., and as long as pets can ingest them, they can be prepared in the same form as the food and drink compositions mentioned above. can.
  • the content of the formulation contained in the feed is preferably 0.01 to 100% by mass, more preferably 0.1 to 50% by mass, even more preferably 0.2 to 25% by mass. .
  • Method for producing food and drink compositions, pharmaceutical compositions, or feeds There is no restriction on the method for producing the food/beverage composition, pharmaceutical composition, or feed, and any known method can be used to produce the food/drink composition, pharmaceutical composition, or feed.
  • the present invention can provide a sweet taste-enhancing formulation containing an extract of Asitaba.
  • the type and content of component A: chalcone are in accordance with the description of [chalcone-containing preparation] above.
  • the sweetness-enhancing preparation may further contain the above-mentioned component B, component C, and other components.
  • the types and contents of various components are in accordance with the description of [Chalcone-containing preparation] above.
  • the sweet taste enhancing preparation in, for example, a pharmaceutical composition, a quasi-drug, a food/beverage composition, or a feed that requires sweet taste enhancement.
  • the amount of the sweetness enhancing preparation in a pharmaceutical composition, quasi-drug, food/beverage composition, or feed is not limited as long as the effects of the present invention are achieved, but for example, 0.001 to 1% by mass, 0.005-1% by mass, 0.01-1% by mass, 0.02-1% by mass, 0.001-0.8% by mass, 0.005-0.8% by mass, 0.01-0. 8% by mass, 0.02-0.8% by mass, 0.001-0.5% by mass, 0.005-0.5% by mass, 0.01-0.5% by mass, 0.001-0.
  • Examples include 1% by mass, 0.005 to 0.1% by mass, and 0.01 to 0.1% by mass.
  • the type of sweetness mentioned above is not particularly limited, but includes, for example, sucrose.
  • the above-mentioned sweetness enhancement is not particularly limited, but includes, for example, intensity of sweetness, continuation of sweetness, etc.
  • the intensity of sweetness refers to the intensity of sweetness felt immediately after eating.
  • sustained sweetness refers to the intensity of the sweetness felt as a lingering aftertaste 1 to 2 seconds after eating.
  • (A) chalcone
  • (B) contains at least one solubilizing component selected from the group consisting of sucrose fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, enzymatically decomposed lecithin, and saponin;
  • component (A) is at least one selected from the group consisting of 4-hydroxydericin and xanthoangelol.
  • component (B) is at least one selected from the group consisting of sucrose fatty acid ester, glycerin fatty acid ester, and saponin.
  • component (B) is 0.1 to 100 parts by mass per 1 part by mass of component (A).
  • component (B) is 0.5 to 20 parts by mass per 1 part by mass of component (A).
  • the above-mentioned formulation further contains (C) at least one selected from the group consisting of propylene glycol, starch syrup, reduced starch syrup, glycerin, sugar alcohol, monosaccharide, dextrin, and maltodextrin.
  • a sweetness-enhancing preparation containing Acitaba extract A sweetness-enhancing preparation containing Acitaba extract.
  • solubilizing component containing at least one solubilizing component selected from the group consisting of sucrose fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, enzymatically decomposed lecithin, and saponin. Preparation for sweetness enhancement.
  • component (A) is at least one selected from the group consisting of 4-hydroxydericine and xanthoangelol.
  • component (B) is at least one selected from the group consisting of sucrose fatty acid ester, glycerin fatty acid ester, and saponin.
  • component (B) is 0.1 to 100 parts by mass per 1 part by mass of component (A).
  • component (B) is 0.5 to 20 parts by mass per 1 part by mass of component (A).
  • the above-mentioned formulation further contains (C) at least one selected from the group consisting of propylene glycol, starch syrup, reduced starch syrup, glycerin, sugar alcohol, monosaccharide, dextrin, and maltodextrin.
  • each example According to the formulations shown in Tables 1 to 3 below, the above chalcone and various components were prepared by conventional methods to form test formulations for each example. The types and contents of each component are shown in the table below. The dissolution states of the test formulations of each example are shown in Tables 1 to 3 and Figures 2 to 4.
  • the dispersibility of chalcone was improved even when the chalcone content was 0.5% by mass or more based on the total amount of the formulation.
  • polysorbate was used as component B, not only the dispersibility improvement effect of chalcone but also the transparency improvement effect was confirmed.
  • sucrose fatty acid ester was used as component B, and various types of component (C) were further included, and solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • the dissolution state of the test formulations of each example is shown in Table 2 and FIG. 3. Erythritol was used as the sugar alcohol (the same applies to the following examples).
  • propylene glycol (PG) was used as component C, and the solubilizing component (B) was further included, and solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • the dissolution state of the test formulations of each example is shown in Table 3 and Figures 4 and 5.
  • component B glycerin fatty acid ester
  • component (C) various types of component (C) were further included, and solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • the dissolution state of the test formulations of each example is shown in Table 4 and FIG. 6.
  • saponin derived from Quillaya
  • component B saponin (derived from Quillaya)
  • component C various types of component (C) were also included, and solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • Table 5 and FIG. 7 show the dissolution state of the test formulations of each example.
  • propylene glycol (PG) was used as component C, and the solubilizing component (B) was further included, and solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • the dissolution state of the test formulations of each example is shown in Table 6 and FIG. 8.
  • sucrose fatty acid ester was used as component B, and various solubilizing components (C) were further included, and solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • the dissolution state of the test formulations of each example is shown in Table 7 and FIG. 9.
  • component B was glycerin fatty acid ester, and various solubilizing components (C) were further included, and solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • Table 8 and FIG. 9 show the dissolution state of the test formulations of each example.
  • saponin derived from Quillaya
  • solubilizing components C
  • solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • Table 9 and FIG. 9 show the dissolution state of the test formulations of each example.
  • propylene glycol (PG) was used as component C, and the solubilizing component (B) was further included, and solubility evaluation was conducted in the same manner.
  • the types and contents of each component are shown in the table below.
  • the dissolution state of the test formulations of each example is shown in Table 10 and FIG. 10.
  • the effect of enhancing the sweetness of foods and drinks was confirmed in the chalcone-containing preparations.
  • the chalcone in the preparation contains 4-hydroxydericine and xanthoangelol, and the content of xanthoangelol per 1 part by mass of 4-hydroxydericine The amount is about 1.7-1.9 parts by weight.
  • phase A 1 to 3 are stirred and dissolved at 50°C (phase A). 4 to 6 are stirred and dissolved at room temperature (phase B). Add and mix Phase A while stirring Phase B with a paddle to prepare a water-based lotion.
  • a and B are each weighed into a beaker and mixed. Gradually add B while stirring A and mix to prepare a mouthwash.
  • phase A heat and dissolve 1 to 4 to 70°C (phase A). Heat 5 to 7 to 70°C and dissolve them (Phase B). While stirring Phase A with a homomixer, add Phase B and emulsify (2500 rpm, 3 minutes). Thereafter, the mixture is cooled to 30°C while stirring with a paddle to prepare bath milk.
  • phase A 1 to 6 are stirred and dissolved at room temperature (phase A).
  • phase B room temperature
  • a hair tonic is prepared by adding and dissolving phase A while stirring phase B with a paddle.
  • each blended raw material is mixed, sterilized, and filled into bottles to prepare a seasoning liquid for pickles.
  • each blended raw material is mixed, sterilized, and filled into bottles to prepare noodle soup.
  • the raw materials are mixed, sterilized at 140°C for 45 seconds, and filled into plastic bottles.
  • the raw materials are mixed, sterilized at 140°C for 45 seconds, and filled into plastic bottles.
  • the raw materials are mixed, sterilized at 140°C for 45 seconds, and filled into plastic bottles.
  • black tea is extracted with water at 80°C for 10 minutes, other ingredients are added, sterilized at 137°C for 50 seconds, and filled into plastic bottles.
  • green tea is extracted with 70°C water for 10 minutes, other raw materials are added, sterilized at 137°C for 40 seconds, and filled into plastic bottles.
  • oolong tea is extracted with water at 90°C for 10 minutes, other raw materials are added, sterilized at 137°C for 40 seconds, and filled into plastic bottles.
  • rooibos is extracted with water at 90° C. for 10 minutes, other raw materials are added, sterilized at 140° C. for 50 seconds, and filled into plastic bottles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2023/010245 2022-03-29 2023-03-16 カルコン含有製剤 Ceased WO2023189643A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024511780A JPWO2023189643A1 (enExample) 2022-03-29 2023-03-16

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-054024 2022-03-29
JP2022054024 2022-03-29

Publications (1)

Publication Number Publication Date
WO2023189643A1 true WO2023189643A1 (ja) 2023-10-05

Family

ID=88201805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/010245 Ceased WO2023189643A1 (ja) 2022-03-29 2023-03-16 カルコン含有製剤

Country Status (2)

Country Link
JP (1) JPWO2023189643A1 (enExample)
WO (1) WO2023189643A1 (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112817A1 (ja) * 2003-06-20 2004-12-29 Takara Bio Inc. セリ科植物由来抽出物およびその製造方法
JP2007176919A (ja) * 2005-05-19 2007-07-12 Takara Bio Inc カルコン類化合物含有組成物
JP2010090042A (ja) * 2008-10-06 2010-04-22 Tsujido Chemical Corp 治療剤
KR20120061262A (ko) * 2010-12-03 2012-06-13 (주)바이오제닉스 칼콘계 화합물 함유 수계 가용화 조성물, 이를 이용한 미백 기능성 화장용 조성물 및 이들의 제조 방법
JP2013067585A (ja) * 2011-09-22 2013-04-18 Lotte Co Ltd 消臭組成物
JP2015067539A (ja) * 2013-09-26 2015-04-13 ライオン商事株式会社 抗菌剤、歯周病予防剤及びペット用口腔用組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112817A1 (ja) * 2003-06-20 2004-12-29 Takara Bio Inc. セリ科植物由来抽出物およびその製造方法
JP2007176919A (ja) * 2005-05-19 2007-07-12 Takara Bio Inc カルコン類化合物含有組成物
JP2010090042A (ja) * 2008-10-06 2010-04-22 Tsujido Chemical Corp 治療剤
KR20120061262A (ko) * 2010-12-03 2012-06-13 (주)바이오제닉스 칼콘계 화합물 함유 수계 가용화 조성물, 이를 이용한 미백 기능성 화장용 조성물 및 이들의 제조 방법
JP2013067585A (ja) * 2011-09-22 2013-04-18 Lotte Co Ltd 消臭組成物
JP2015067539A (ja) * 2013-09-26 2015-04-13 ライオン商事株式会社 抗菌剤、歯周病予防剤及びペット用口腔用組成物

Also Published As

Publication number Publication date
JPWO2023189643A1 (enExample) 2023-10-05

Similar Documents

Publication Publication Date Title
EP3614860B1 (en) Sweetness and taste improvement of steviol glycoside and mogroside sweeteners with dihydrochalcones
RU2656390C2 (ru) Композиции и способы повышения растворимости ребаудиозида м
JP6779287B2 (ja) 改善された香味プロファイルを有するステビオールグリコシド甘味料
CN107249356B (zh) 用于口服摄入或使用的甜菊醇糖苷化合物、组合物以及用于增强甜菊醇糖苷溶解度的方法
CN106795523B (zh) 制备莱鲍迪苷i的方法以及用途
RU2599166C2 (ru) Способы очистки стевиоловых гликозидов и их применение
CN108289489B (zh) 用于口服摄取或使用的甜菊醇糖苷组合物
WO2019071182A1 (en) STEVIOL GLYCOSIDE SOLUBILITY AMPLIFIERS
BR112017004240B1 (pt) Processo para preparar uma composição de glicosídeo de esteviol aquoso não tratado, extrato de stevia aquoso não tratado preparado pelo referido processo e alimento ou bebida
TW200738174A (en) High-potency sweetener composition with antioxidant and compositions sweetened therewith
US11584769B2 (en) Diterpene glycosides, compositions and purification methods
JP7107855B2 (ja) 経口摂取のためのステビオール配糖体組成物または使用
BR112015014876B1 (pt) rebaudiosídeo x amorfo, composição edulcorante compreendendo o dito rebaudiosídeo x, método para preparar o rebaudiosídeo x amorfo e método para preparar uma bebida
KR20120065961A (ko) 고순도 레바우디오사이드 ｄ 및 적용
CN115211549A (zh) 掺入了莱苞迪苷n的甜味剂组合物和经甜化的组合物
JP2019517812A (ja) 経口摂取または経口使用のためのステビオールグリコシド組成物
KR102628901B1 (ko) 구강내 감미제 조성물 및 방법
CN118697017A (zh) 具有类黄酮的甜菊醇糖苷或罗汉果苷甜味剂的甜度和味道改善
JP2022521762A (ja) 新規モグロシド及びその使用
JP7457510B2 (ja) 野菜／果物劣化臭マスキング剤、並びにその使用
WO2023189643A1 (ja) カルコン含有製剤
EP3223631A1 (en) Novel diterpene glycoside, compositions and purification methods
HK40028167A (en) Sweetness and taste improvement of steviol glycoside and mogroside sweeteners with dihydrochalcones
HK40028167B (zh) 二氢查耳酮对甜菊醇糖苷和罗汉果苷甜味剂的甜度和味道改善
HK40002873A (en) Sweetness and taste improvement of steviol glycoside or mogroside sweeteners with flavonids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23779661

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024511780

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23779661

Country of ref document: EP

Kind code of ref document: A1